Answers are grounded in this paper and cite their sources.
Li–Fraumeni syndrome (LFS) is classically characterised by early-onset cancers and strong family history. De novo TP53 mutations also contribute to the disease burden. However, due to their atypical presentation, they fail to be recognised as per the current diagnostic criteria. We report a 51-year-old female with no personal or family history of cancer, incidentally diagnosed with synchronous pulmonary adenocarcinoma and triple-negative breast carcinoma during a routine health check-up. After neoadjuvant chemotherapy, surgery, radiotherapy and targeted therapy, a metachronous third malignancy – pancreatic undifferentiated carcinoma – was detected within the same year. Germline genetic testing revealed a pathogenic TP53 mutation (p.Arg248Gln). The extended family history showed no cancer across four generations. The mutation was absent in both her children too. This case illustrates an atypical presentation, not fulfilling classic or Chompret criteria. Despite harbouring a hotspot TP53 mutation, the patient presented with cancers at a later age, highlighting variable expressivity and limitations in current diagnostic criteria. Literature review shows a growing number of patients with pathogenic TP53 mutations outside existing clinical frameworks, suggesting the need for expanded criteria and broader awareness of LFS. Clinicians should maintain a high index of suspicion for hereditary cancer syndromes even in the absence of suggestive family history or classic clinical patterns. Early identification through comprehensive genetic testing enables timely surveillance and intervention, potentially improving outcomes in patients with germline TP53 mutations.
No takes yet. Share an insight, caveat, or question.
Tirumala et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: